Insmed Incorporated (NASDAQ:INSM) Shares Sold by Marshall Wace LLP

Marshall Wace LLP cut its position in Insmed Incorporated (NASDAQ:INSM) by 6.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,249,351 shares of the biopharmaceutical company’s stock after selling 80,697 shares during the quarter. Marshall Wace LLP’s holdings in Insmed were worth $83,707,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EntryPoint Capital LLC acquired a new position in Insmed in the 1st quarter valued at about $33,000. Fidelis Capital Partners LLC purchased a new stake in Insmed during the 1st quarter worth approximately $34,000. First Horizon Advisors Inc. lifted its holdings in Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares in the last quarter. Headlands Technologies LLC purchased a new position in Insmed in the 1st quarter valued at approximately $59,000. Finally, CWM LLC grew its stake in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares in the last quarter.

Insmed Trading Up 1.1 %

Shares of NASDAQ INSM opened at $72.63 on Wednesday. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05. The stock has a 50 day moving average of $74.46 and a two-hundred day moving average of $52.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same period last year, the business posted ($1.78) EPS. Insmed’s revenue was up 17.0% compared to the same quarter last year. On average, research analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wells Fargo & Company increased their price objective on Insmed from $55.00 to $77.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. Morgan Stanley lifted their price objective on Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Evercore ISI upped their target price on shares of Insmed from $42.00 to $75.00 and gave the stock an “outperform” rating in a research note on Friday, June 21st. Truist Financial reduced their target price on shares of Insmed from $88.00 to $85.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Finally, Stifel Nicolaus boosted their price target on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $81.40.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,882 shares of company stock worth $5,765,446. Company insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.